Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets

Transfusion

Volumn 56, Issue 6, 2016, Pages 1419-1429

  Muench, Marcus O ^a,b   Heitman, John W ^a   Inglis, Heather ^a   Fomin, Marina E ^a   Marschner, Susanne ^b   Goodrich, Raymond P ^b   Norris, Philip J ^a,b,c   Jackman, Rachael P ^a,b  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Scientific and Clinical Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ALLOANTIGEN; ANTISERUM; RIBOFLAVIN;

ALLOIMMUNITY; ALLOIMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DONOR; EX VIVO STUDY; FEMALE; IMMUNOGENICITY; LEUKOCYTE; MALE; MOUSE; NONHUMAN; PATHOGEN REDUCED PLATELET TRANSFUSION; REPEAT PROCEDURE; THROMBOCYTE TRANSFUSION; ULTRAVIOLET RADIATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BLOODBORNE BACTERIUM; C57BL MOUSE; IMMUNOLOGICAL TOLERANCE; LEUKAPHERESIS; MICROBIOLOGY; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; BLOOD-BORNE PATHOGENS; FEMALE; IMMUNE TOLERANCE; ISOANTIBODIES; LEUKOCYTE REDUCTION PROCEDURES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLATELET TRANSFUSION; RIBOFLAVIN; ULTRAVIOLET RAYS;

EID: 84962630339     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13579     Document Type: Article

References (41)

1. Howard JE, Perkins HA., The natural history of alloimmunization to platelets. Transfusion 1978; 18: 496-503.
2. Itescu S, Tung TC, Burke EM, et al., Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 1998; 98: 786-93.
3. Massad MG, Cook DJ, Schmitt SK, et al., Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg 1997; 64: 1120-5.
4. Moazami N, Itescu S, Williams MR, et al., Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant 1998; 17: 876-80.
5. Slichter SJ, Davis K, Enright H, et al., Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105: 4106-14.
6. Tsau PH, Arabía FA, Toporoff B, et al., Positive panel reactive antibody titers in patients bridged to transplantation with a mechanical assist device: risk factors and treatment. ASAIO J 1998; 44: M634-7.
7. [No authors listed]. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861-9.
8. Andreu G, Fressy P., Transfusion-associated graft-versus-host disease (TA-GVHD): cellular mechanisms and their possible modulation by ultraviolet radiation. Transfus Sci 1995; 16: 109-13.
9. Dutcher JP, Schiffer CA, Aisner J, et al., Alloimmunization following platelet transfusion: the absence of a dose-response relationship. Blood 1981; 57: 395-8.
10. Fauchet R, Genetet B, Gueguen M, et al., Transfusion therapy and HLA antibody response in patients undergoing open heart surgery. Transfusion 1982; 22: 320-2.
11. Fisher M, Chapman JR, Ting A, et al., Alloimmunisation to HLA antigens following transfusion with leucocyte-poor and purified platelet suspensions. Vox Sang 1985; 49: 331-5.
12. Karpinski M, Pochinco D, Dembinski I, et al., Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrol 2004; 15: 818-24.
13. Murphy MF, Metcalfe P, Thomas H, et al., Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 1986; 62: 529-34.
14. Schiffer CA, Dutcher JP, Aisner J, et al., A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983; 62: 815-20.
15. van Marwijk Kooy M, van Prooijen HC, Moes M, et al., Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 1991; 77: 201-5.
16. Andreu G, Dewailly J, Leberre C, et al., Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988; 72: 964-9.
17. Jackman RP, Deng X, Bolgiano D, et al., Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response. Transfusion 2014; 54: 672-80.
18. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, et al., Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 1995; 85: 824-8.
19. Sniecinski I, O'Donnell MR, Nowicki B, et al., Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988; 71: 1402-7.
20. Fast LD, Dileone G, Li J, et al., Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006; 46: 642-8.
21. Jackman RP, Heitman JW, Marschner S, et al., Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment. Transfusion 2009; 49: 2686-99.
22. Jackman RP, Muench MO, Heitman JW, et al., Immune modulation and lack of alloimmunization following transfusion with pathogen-reduced platelets in mice. Transfusion 2013; 53: 2697-709.
23. Babic AM., Extracorporeal photopheresis: lighting the way to immunomodulation. Am J Hematol 2008; 83: 589-91.
24. Knobler R., Extracorporeal photochemotherapy - present and future. Vox Sang 2000; 78 Suppl 2: 197-201.
25. Oliven A, Shechter Y., Extracorporeal photopheresis: a review. Blood Rev 2001; 15: 103-8.
26. Russo GG, Mullen C., Cutaneous and noncutaneous disorders treated with extracorporeal photopheresis. Int J Dermatol 2001; 40: 89-100.
27. Lamioni A, Carsetti R, Legato A, et al., Induction of regulatory T cells after prophylactic treatment with photopheresis in renal transplant recipients. Transplantation 2007; 83: 1393-6.
28. Lamioni A, Parisi F, Isacchi G, et al., The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 2005; 79: 846-50.
29. Blundell EL, Pamphilon DH, Fraser ID, et al., A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy. Transfusion 1996; 36: 296-302.
30. Kao KJ., Induction of humoral immune tolerance to major histocompatibility complex antigens by transfusions of UVB-irradiated leukocytes. Blood 1996; 88: 4375-82.
31. Fontão-Wendel R, Silva LC, Saviolo CB, et al., Incidence of transfusion-induced platelet-reactive antibodies evaluated by specific assays for the detection of human leucocyte antigen and human platelet antigen antibodies. Vox Sang 2007; 93: 241-9.
32. Kurz M, Greinix H, Höcker P, et al., Specificities of anti-platelet antibodies in multitransfused patients with haemato-oncological disorders. Br J Haematol 1996; 95: 564-9.
33. Jackman RP, Deng X, Bolgiano D, et al., Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants. Blood 2013; 121: 3261-6; quiz 3299.
34. Waterman HR, Kapp LM, Munday A, et al., Transfusion-induced alloimmunization and platelet refractoriness in a mouse model: mechanisms and interventions. Transfusion 2016; 56: 91-100.
35. Gilson CR, Patel SR, Zimring JC., CTLA4-Ig prevents alloantibody production and BMT rejection in response to platelet transfusions in mice. Transfusion 2012; 52: 2209-19.
36. Alter HJ., Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev 2008; 22: 97-102.
37. Kleinman S., Pathogen inactivation: emerging indications. Curr Opin Hematol 2015; 22: 547-53.
38. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50: 2362-75.
39. AuBuchon JP, Herschel L, Roger J, et al., Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335-41.
40. Marschner S, Fast LD, Baldwin WM 3rd, et al., White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 2010; 50: 2489-98.
41. Carrick DM, Norris PJ, Endres RO, et al., Establishing assay cutoffs for HLA antibody screening of apheresis donors. Transfusion 2011; 51: 2092-101.